Clinical Trial Update: AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer [Phase 1]

View source ↗

Summary

AB-1015 is an integrated circuit T cell therapy being studied in a Phase 1 trial for platinum-resistant epithelial ovarian cancer; the trial status is ACTIVE_NO…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• AB-1015

Snippet

Sponsor: Arsenal Biosciences, Inc. | Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING